Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Precipio Sued Over Transgenomic Securities Agreement

Precipio Sued Over Transgenomic Securities Agreement

Feb 27, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Molecular diagnostics firm Precipio has been sued for more than $2 million by Crede Capital Group over an alleged violation of a securities agreement between the investment group and Transgenomic, which Precipio acquired last year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. BioReference Settles False Claims, Kickback Allegations for $11.5M

  2. United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

  3. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

  4. Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

  5. FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.